Psycheceutical Bioscience, Inc. Faced with Enduring Regulatory Challenges

MIAMI, FL—Psycheceutical Bioscience, Inc., a prominent bioscience company, has publicly addressed its continuous struggle with regulatory filing deficiencies which have been obstructing corporate actions like name and symbol changes, mergers and acquisitions, and reverse splits for over a decade. Despite these setbacks, which typically lead companies to insolvency and potential bankruptcy, Psycheceutical is actively seeking ways to prevent such outcomes.

Neilank K. Jha, MD, Executive Chairman & CEO of Psycheceutical, stated that the company is collaboratively working with various professionals to navigate these challenges. He also emphasized their commitment to maintaining transparency with shareholders and expects to share updates on their progress soon. Psycheceutical remains optimistic about its future plans enhancing shareholder value despite ongoing regulatory hurdles.